Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;11(3):481-484.
doi: 10.21037/hbsn-21-569.

Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trial

Amalia Gastaldelli  1
Affiliations
Editorial

Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trial

Amalia Gastaldelli. Hepatobiliary Surg Nutr. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-569/coif). The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The complex role of PPARs in liver and peripheral organs, and their involvement in NASH and liver fibrosis. Three PPAR isotypes have been identified, PPARα, PPARγ and PPARβ/δ, differentially expressed in tissues and cell types with different functions (red and blue). Effects of treatment with PPAR agonists (single PPAR or multiple PPAR activation) are shown (in the pink boxes). In NASH, PPARs agonists improve lipid metabolism by modulating lipid fluxes (lipolysis, lipogenesis and lipoprotein secretion), regulating the transport and oxidation of fatty acid. They also reduce insulin resistance by decreasing hepatic glucose production and increasing peripheral glucose uptake. In addition, they reduce inflammation in the liver and the whole body. Taken together, the three PPAR isotypes improve NASH and fibrosis by targeting the multiple pathways involved in the development of NASH and its progression. FAO, fatty acid oxidation; HDL, high density lipoproteins; PPAR, peroxisome proliferator activated receptor; TG, triglyceride; FFA, free fatty acid.
See this image and copyright information in PMC

Comment on

  • A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.

References

    1. Guerra S, Mocciaro G, Gastaldelli A. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. Eur J Clin Invest 2022;52:e13695. 10.1111/eci.13695 - DOI - PubMed
    1. Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. 10.1007/s00125-021-05442-2 - DOI - PMC - PubMed
    1. Parlati L, Régnier M, Guillou H, et al. New targets for NAFLD. JHEP Rep 2021;3:100346. 10.1016/j.jhepr.2021.100346 - DOI - PMC - PubMed
    1. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997;94:4312-7. 10.1073/pnas.94.9.4312 - DOI - PMC - PubMed
    1. Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab 2011;96:1424-30. 10.1210/jc.2010-2129 - DOI - PubMed